Shares of Geron Corp. rose Tuesday after the company said that based clinical research on embryonic stem cell therapy for spinal cord injuries began.

SPARK: Monday, “the company said that its first patient enrolled in phase 1, or to learn at an early stage in the center of the study is the safety, tolerability, and not only its effectiveness check ..

The Big Picture: embryonic stem cells, the embryo, have the ability to be any type of cell. The study, which was to be expected, is the first study was approved by the FDA for the treatment of embryonic stem cells.

Comment: Renee Benjamin, Rodman Renshaw and analysts to “beat the market” rating and a price target of $ 9 per share. He said the inclusion of patients in the study “a milestone represents a transformation of the throat.”

Social activities: up to 33 cents, or 5.8 percent, to $ 6 in trading Tuesday morning. The stock traded between $ 4.37 and $ 7.18 in 52 weeks.